{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:59:46Z","timestamp":1794909586205,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University of Shizuoka academic research grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04866-0","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:21:38Z","timestamp":1772778098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["NFE2L2 rs35652124C&gt;T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0744-7425","authenticated-orcid":false,"given":"Hisanaga","family":"Nomura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-8334","authenticated-orcid":false,"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4436-0529","authenticated-orcid":false,"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-2841","authenticated-orcid":false,"given":"Daiki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"1","key":"4866_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19(1):68\u201374. https:\/\/doi.org\/10.1245\/s10434-011-2049-9","journal-title":"Ann Surg Oncol"},{"issue":"10447","key":"4866_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, Kojima T, Abe T, Bamba T, Watanabe M, Kawakubo H, Shibuya Y, Tsubosa Y, Takegawa N, Kajiwara T, Baba H, Ueno M, Takeuchi H, Nakamura K, Kitagawa Y (2024) Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 next): a randomised, controlled, open-label, phase 3 trial. Lancet 404(10447):55\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(24)00745-1","journal-title":"Lancet"},{"issue":"11","key":"4866_CR3","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cas.12274","volume":"104","author":"H Hara","year":"2013","unstructured":"Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104(11):1455\u20131460. https:\/\/doi.org\/10.1111\/cas.12274","journal-title":"Cancer Sci"},{"issue":"2","key":"4866_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12282-014-0547-x","volume":"23","author":"M Sugishita","year":"2016","unstructured":"Sugishita M, Imai T, Kikumori T, Mitsuma A, Shimokata T, Shibata T, Morita S, Inada-Inoue M, Sawaki M, Hasegawa Y, Ando Y (2016) Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer. Breast Cancer 23(2):195\u2013201. https:\/\/doi.org\/10.1007\/s12282-014-0547-x","journal-title":"Breast Cancer"},{"key":"4866_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/978-1-4939-0956-8_12","volume":"1175","author":"P Alberti","year":"2014","unstructured":"Alberti P, Cavaletti G (2014) Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy. Methods Mol Biol 1175:301\u2013322. https:\/\/doi.org\/10.1007\/978-1-4939-0956-8_12","journal-title":"Methods Mol Biol"},{"issue":"44","key":"4866_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005151","volume":"95","author":"D Tsuji","year":"2016","unstructured":"Tsuji D, Ikeda M, Yamamoto K, Nakamori H, Kim YI, Kawasaki Y, Otake A, Yokoi M, Inoue K, Hirai K, Nakamichi H, Tokou U, Shiokawa M, Itoh K (2016) Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: a hospital-based observational study. Medicine (Baltimore) 95(44):e5151. https:\/\/doi.org\/10.1097\/MD.0000000000005151","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"4866_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra020021","volume":"348","author":"R Weinshilboum","year":"2003","unstructured":"Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348(6):529\u2013537. https:\/\/doi.org\/10.1056\/NEJMra020021","journal-title":"N Engl J Med"},{"issue":"2","key":"4866_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00280-020-04118-9","volume":"86","author":"H Nomura","year":"2020","unstructured":"Nomura H, Tsuji D, Demachi K, Mochizuki N, Matsuzawa H, Yano T, Daiko H, Fujii S, Kojima T, Itoh K, Kawasaki T (2020) ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Cancer Chemother Pharmacol 86(2):315\u2013324. https:\/\/doi.org\/10.1007\/s00280-020-04118-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7577","key":"4866_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature15726","volume":"527","author":"E Piskounova","year":"2015","unstructured":"Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, DeBerardinis RJ, Morrison SJ (2015) Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527(7577):186\u2013191. https:\/\/doi.org\/10.1038\/nature15726","journal-title":"Nature"},{"issue":"12","key":"4866_CR10","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1111\/cas.16355","volume":"115","author":"T Iwasaki","year":"2024","unstructured":"Iwasaki T, Shirota H, Sasaki K, Ouchi K, Nakayama Y, Oshikiri H, Otsuki A, Suzuki T, Yamamoto M, Ishioka C (2024) Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: a retrospective cohort study. Cancer Sci 115(12):4034\u20134044. https:\/\/doi.org\/10.1111\/cas.16355","journal-title":"Cancer Sci"},{"key":"4866_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1381467","volume":"14","author":"F Chen","year":"2024","unstructured":"Chen F, Xiao M, Hu S, Wang M (2024) Keap1-Nrf2 pathway: a key mechanism in the occurrence and development of cancer. Front Oncol 14:1381467. https:\/\/doi.org\/10.3389\/fonc.2024.1381467","journal-title":"Front Oncol"},{"issue":"2","key":"4866_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2443.2010.01473.x","volume":"16","author":"K Taguchi","year":"2011","unstructured":"Taguchi K, Motohashi H, Yamamoto M (2011) Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16(2):123\u2013140. https:\/\/doi.org\/10.1111\/j.1365-2443.2010.01473.x","journal-title":"Genes Cells"},{"issue":"6","key":"4866_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.tips.2013.04.005","volume":"34","author":"T Suzuki","year":"2013","unstructured":"Suzuki T, Motohashi H, Yamamoto M (2013) Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34(6):340\u2013346. https:\/\/doi.org\/10.1016\/j.tips.2013.04.005","journal-title":"Trends Pharmacol Sci"},{"key":"4866_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.08.007","volume":"173","author":"A Matana","year":"2020","unstructured":"Matana A, Ziros PG, Chartoumpekis DV, Renaud CO, Polasek O, Hayward C, Zemunik T, Sykiotis GP (2020) Rare and common genetic variations in the Keap1\/Nrf2 antioxidant response pathway impact thyroglobulin gene expression and circulating levels, respectively. Biochem Pharmacol 173:113605. https:\/\/doi.org\/10.1016\/j.bcp.2019.08.007","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"4866_CR15","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1111\/jcmm.12874","volume":"20","author":"P Song","year":"2016","unstructured":"Song P, Li K, Liu L, Wang X, Jian Z, Zhang W, Wang G, Li C, Gao T (2016) Genetic polymorphism of the Nrf2 promoter region is associated with vitiligo risk in Han Chinese populations. J Cell Mol Med 20(10):1840\u20131850. https:\/\/doi.org\/10.1111\/jcmm.12874","journal-title":"J Cell Mol Med"},{"issue":"3","key":"4866_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2025.119897","volume":"1872","author":"G Hraoui","year":"2025","unstructured":"Hraoui G, Grondin M, Breton S, Averill-Bates DA (2025) Nrf2 mediates mitochondrial and NADPH oxidase-derived ROS during mild heat stress at 40 degrees C. Biochim Biophys Acta Mol Cell Res 1872(3):119897. https:\/\/doi.org\/10.1016\/j.bbamcr.2025.119897","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"1\u20132","key":"4866_CR17","first-page":"113","volume":"76","author":"Y Shimoyama","year":"2014","unstructured":"Shimoyama Y, Mitsuda Y, Hamajima N, Niwa T (2014) Polymorphisms of Nrf2, an antioxidative gene, are associated with blood pressure in Japanese. Nagoya J Med Sci 76(1\u20132):113\u2013120","journal-title":"Nagoya J Med Sci"},{"issue":"12","key":"4866_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1152\/physiolgenomics.00178.2013","volume":"46","author":"SM Figarska","year":"2014","unstructured":"Figarska SM, Vonk JM, Boezen HM (2014) NFE2L2 polymorphisms, mortality, and metabolism in the general population. Physiol Genomics 46(12):411\u2013417. https:\/\/doi.org\/10.1152\/physiolgenomics.00178.2013","journal-title":"Physiol Genomics"},{"key":"4866_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9825028","volume":"2020","author":"R Teena","year":"2020","unstructured":"Teena R, Dhamodharan U, Ali D, Rajesh K, Ramkumar KM (2020) Genetic polymorphism of the Nrf2 promoter region (rs35652124) is associated with the risk of diabetic foot ulcers. Oxid Med Cell Longev 2020:9825028. https:\/\/doi.org\/10.1155\/2020\/9825028","journal-title":"Oxid Med Cell Longev"},{"issue":"21","key":"4866_CR20","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/0008-5472.CAN-12-1474","volume":"72","author":"JM Hartikainen","year":"2012","unstructured":"Hartikainen JM, Tengstrom M, Kosma VM, Kinnula VL, Mannermaa A, Soini Y (2012) Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer. Cancer Res 72(21):5537\u20135546. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1474","journal-title":"Cancer Res"},{"issue":"3","key":"4866_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/genes14030718","volume":"14","author":"LN Porokhovnik","year":"2023","unstructured":"Porokhovnik LN, Pisarev VM, Chumachenko AG, Chudakova JM, Ershova ES, Veiko NN, Gorbachevskaya NL, Mamokhina UA, Sorokin AB, Basova AY, Lapshin MS, LI V, Kostyuk SV (2023) Association of NEF2L2 Rs35652124 polymorphism with Nrf2 induction and genotoxic stress biomarkers in autism. Genes (Basel) 14(3):718. https:\/\/doi.org\/10.3390\/genes14030718","journal-title":"Genes (Basel)"},{"issue":"5","key":"4866_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/j.1349-7006.2008.00765.x","volume":"99","author":"K Kiyotani","year":"2008","unstructured":"Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 99(5):967\u2013972. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00765.x","journal-title":"Cancer Sci"},{"issue":"12","key":"4866_CR23","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1002\/ijc.27567","volume":"131","author":"D Campa","year":"2012","unstructured":"Campa D, Muller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F, Risch A (2012) A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer 131(12):2920\u20132928. https:\/\/doi.org\/10.1002\/ijc.27567","journal-title":"Int J Cancer"},{"issue":"3","key":"4866_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4143\/crt.2014.012","volume":"47","author":"JR Choi","year":"2015","unstructured":"Choi JR, Kim JO, Kang DR, Shin JY, Zhang XH, Oh JE, Park JY, Kim KA, Kang JH (2015) Genetic variations of drug transporters can influence on drug response in patients treated with docetaxel chemotherapy. Cancer Res Treat 47(3):509\u2013517. https:\/\/doi.org\/10.4143\/crt.2014.012","journal-title":"Cancer Res Treat"},{"issue":"2","key":"4866_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00280-021-04374-3","volume":"89","author":"M Yan","year":"2022","unstructured":"Yan M, Fan X, Si H, Wang X, Wang Z, Wang Z, Lv X, Yin H, Jia Y, Jiang L, Xia Y, Liu Y (2022) Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis. Cancer Chemother Pharmacol 89(2):173\u2013181. https:\/\/doi.org\/10.1007\/s00280-021-04374-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4866_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4161\/cbt.18920","volume":"13","author":"M Ji","year":"2012","unstructured":"Ji M, Tang J, Zhao J, Xu B, Qin J, Lu J (2012) Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biol Ther 13(5):264\u2013271. https:\/\/doi.org\/10.4161\/cbt.18920","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"4866_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.31557\/APJCP.2021.22.1.3","volume":"22","author":"Q Chen","year":"2021","unstructured":"Chen Q, Lin W, Yang J, Lin M, Lin X, Weng Y, Chen Y (2021) Prognostic value of two polymorphisms, rs1045642 and rs1128503, in ABCB1 following taxane-based chemotherapy: a meta-analysis. Asian Pac J Cancer Prev 22(1):3\u201310. https:\/\/doi.org\/10.31557\/APJCP.2021.22.1.3","journal-title":"Asian Pac J Cancer Prev"},{"key":"4866_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2024.108995","volume":"445","author":"T Fujikawa","year":"2024","unstructured":"Fujikawa T, Ito T, Okada R, Sawada M, Mohri K, Tateishi Y, Takahashi R, Asakage T, Tsutsumi T (2024) Combined genetic polymorphisms of the GSTT1 and NRF2 genes increase susceptibility to cisplatin-induced ototoxicity: a preliminary study. Hear Res 445:108995. https:\/\/doi.org\/10.1016\/j.heares.2024.108995","journal-title":"Hear Res"},{"key":"4866_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7582730","volume":"2018","author":"S Gorini","year":"2018","unstructured":"Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E (2018) Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev 2018:7582730. https:\/\/doi.org\/10.1155\/2018\/7582730","journal-title":"Oxid Med Cell Longev"},{"key":"4866_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.redox.2017.08.003","volume":"14","author":"J Deng","year":"2018","unstructured":"Deng J, Zhong YF, Wu YP, Luo Z, Sun YM, Wang GE, Kurihara H, Li YF, He RR (2018) Carnosine attenuates cyclophosphamide-induced bone marrow suppression by reducing oxidative DNA damage. Redox Biol 14:1\u20136. https:\/\/doi.org\/10.1016\/j.redox.2017.08.003","journal-title":"Redox Biol"},{"issue":"2","key":"4866_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3164\/jcbn.14-134","volume":"56","author":"K Itoh","year":"2015","unstructured":"Itoh K, Ye P, Matsumiya T, Tanji K, Ozaki T (2015) Emerging functional cross-talk between the Keap1-Nrf2 system and mitochondria. J Clin Biochem Nutr 56(2):91\u201397. https:\/\/doi.org\/10.3164\/jcbn.14-134","journal-title":"J Clin Biochem Nutr"},{"key":"4866_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100028","volume":"2","author":"J Wang","year":"2021","unstructured":"Wang J, Yang J, Cao M, Zhao Z, Cao B, Yu S (2021) The potential roles of Nrf2\/Keap1 signaling in anticancer drug interactions. Curr Res Pharmacol Drug Discov 2:100028. https:\/\/doi.org\/10.1016\/j.crphar.2021.100028","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"4","key":"4866_CR33","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00520-019-05001-x","volume":"28","author":"H Nomura","year":"2020","unstructured":"Nomura H, Hatogai K, Maki Y, Mochizuki N, Tanaka M, Saito S, Daiko H, Kojima T, Kawasaki T (2020) Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer 28(4):1849\u20131854. https:\/\/doi.org\/10.1007\/s00520-019-05001-x","journal-title":"Support Care Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04866-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04866-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04866-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:21:40Z","timestamp":1772778100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04866-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4866"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04866-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7807601\/v1","asserted-by":"object"}]},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the institutional review board of the NCC, Japan in March 2017 (2016\u2013384). These patients were consented to be used the clinical information and DNA sample in the National Cancer Center (NCC) Biobank Registry. The study design is displayed on the website for the National Cancer Center Hospital East, providing the relatives of deceased patients the opportunity to decline participation in the current study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"23"}}